Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™

SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the New Drug Application (“NDA”) of Vitaros™ (alprostadil, DDAIP.HCl), a topical cream … [Read more...]

Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results

 Company Provides 2018 Financial Guidance and Expected Milestones; Reduced Operating Expenses vs. 2017; Over Two Years of Cash Based on Current Burn Rate CK-2127107 Advancing in Four Clinical Trials Under Collaboration with Astellas; Results Expected in 2018 with Data from Phase 2 Clinical Trial in Patients with SMA Anticipated in Q2 Enrollment in GALACTIC-HF on Track Under … [Read more...]

Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia

PARSIPPANY, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), announced today that the U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products Advisory Committee did not reach a unanimous decision on the efficacy and safety of the use of EXPAREL® (bupivacaine liposome injectable suspension) as a nerve block to produce … [Read more...]

Sodium Acetate Market worth $220mn by 2024: Global Market Insights, Inc.

Sellbyville, Delaware, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Global Sodium Acetate Market is predicted to reach USD 220 million by 2024; according to a new research report by Global Market Insights. Over the recent years, sodium acetate industry has witnessed a remarkable progression across the world due to the rapid industrialization, massive FDI investment, and other factors … [Read more...]

Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the RBC Capital Markets Global Healthcare Conference on Thursday, February 22, 2018 at 10:00 AM ET at the Lotte New York Palace Hotel in New York. … [Read more...]